Saluda Medical (ASX:SLD) said the first procedures in the US using the Evoke CAP24 surgical paddle lead were performed on Friday, July 10, and Tuesday, July 14, according to a Thursday Australian bourse filing.
Its Evoke system is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy.
Its shares jumped 3% in recent trading on Thursday.